Intellia Therapeutics (NTLA) Cash & Equivalents (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash & Equivalents data on file, last reported at $134.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 6.16% year-over-year to $134.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.7 million (up 6.16% YoY) and the FY2025 annual result came in at $155.5 million, down 17.82% from the prior year.
• Cash & Equivalents eased to $134.7 million in Q1 2026 per NTLA's latest filing, from $155.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $523.5 million in Q4 2022 and bottomed at $120.5 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $156.2 million (2025), against an average of $187.4 million.
• Peak annual rise in Cash & Equivalents reached 317.18% in 2022, while the deepest fall reached 57.82% in 2022.
• Tracing NTLA's Cash & Equivalents over 5 years: stood at $523.5 million in 2022, then sank by 56.69% to $226.7 million in 2023, then fell by 16.57% to $189.2 million in 2024, then fell by 17.82% to $155.5 million in 2025, then decreased by 13.36% to $134.7 million in 2026.
• Per Business Quant, the three latest NTLA Cash & Equivalents figures stand at $134.7 million (Q1 2026), $155.5 million (Q4 2025), and $193.4 million (Q3 2025).

Peer Comparison